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Introduction
Invasive candidiasis (IC) is common in extremely premature infants and causes substantial
morbidity and mortality.1, 2 Up to 30% of infants with IC die,3–5 and nearly 60% of
survivors suffer from neurodevelopmental impairment.2 Risk factors for IC include lower
gestational age, exposure to broad spectrum antibiotics, and presence of central venous
catheters.6 Appropriate dosing of antifungals is needed to prevent death and IC-related
morbidities in this population.
The most commonly used first line antifungals to treat IC in infants are amphotericin B
deoxycholate and fluconazole.7 Amphotericin B deoxycholate is associated with
nephrotoxicity in adults8, 9, and has limited pharmacokinetic (PK) and dosing data in the
premature patient population. Fluconazole has potential therapeutic advantages over
amphotericin B deoxycholate. Fluconazole has an excellent safety profile and is effective at
treating >90% of Candida isolates causing IC in premature infants.6 Additionally,
fluconazole has excellent cerebral spinal fluid (CSF) penetration10 and is excreted, nearly
unchanged, in the urine. As a result, the use of fluconazole as an alternative for treatment
against IC has been increasing in neonatal intensive care units NICU) over the past 10
years.11, 12
Fluconazole, a synthetic triazole, is a highly selective inhibitor of lanosterol 14-α-
demethylase, a fungal cytochrome P450 enzyme13. This enzyme is responsible for
converting lanosterol to ergosterol. This loss of normal sterols in the cell wall induces fungal
cell lysis and death, with minimal effect on mammalian cells. Fluconazole is approved by
the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in
adults for the treatment of vaginal candidiasis, oropharyngeal and esophageal candidiasis,
and cryptococcal meningitis. Additionally the EMA includes indications for invasive
candidiasis, dermatomycosis, coccidiomycosis, and onychomycosis. Fluconazole is labeled
by the EMA for use in term newborn infants and children aged 0–17 years for the treatment
of mucosal candidiasis, IC, cryptococcal meningitis, and prophylaxis of IC in
immunocompromised children. Though not formally indicated for use, the FDA label states
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that fluconazole is efficacious in children 6 months through 13 years for the treatment of
oropharyngeal candidiasis.13–15
In this article, we will review the fluconazole PK and safety in adults and children, followed
by a literature review of the PK and safety in premature infants.
Fluconazole PK and Safety in Adults
Fluconazole PK is well described in the adult population. The volume of distribution (V) is
similar to that of body water (0.7 L/kg). Fluconazole has low plasma protein binding
(11%)16 and is renally cleared as predominately unchanged drug, with metabolism
accounting for only a minimal component of clearance (CL), 0.23 mL/min/kg.17 Systemic
exposure has a linear relation to dose, and plasma half-life (t½) is 30 hours. The
recommended dosing for peripheral infections is 100 – 200 mg every 24 hours, and dosing
for systemic infections in neutropenic patients range from 400 – 800 mg daily.12
A 24-hour area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio
model is predictive of treatment efficacy.17, 18 Experimentally, an AUC/MIC ratio >50 is
>70% efficacious for both mucosal and invasive infections. When treating Candida
infections, an MIC breakpoint of ≤8 µg/mL requires a minimum fluconazole AUC of 400
mg*h/L for effective treatment.12, 19, 20
Fluconazole is generally well tolerated in adults. Elevated liver transaminases have been
documented, but are not dose-dependent and typically resolve with discontinuation of
treatment.16, 21 Fluconazole also rarely causes a nondescript rash.13
Fluconazole PK and Safety in Children
Fluconazole PK in children is less well described. In 101 children22, stratified by age (3
months – 2 years; 2 – 12 years; 12 – 16 years), the PK paramaters changed during growth
and development. The V in the youngest group was higher than in adults but was similar to
adults in the oldest group (0.95 L/kg and 0.7 L/kg). The half-life (t½) was similar across all
three pediatric age groups (21.4 h, 22.7 h, 21.4 h). The shorter t½ (67% that of adults) and
larger V (133% that of adults) observed in this study suggested that an increased dose (6–12
mg/kg body weight) for children > 3 months of age should be used for IC.22
Fluconazole has been shown to be safe in children. The largest review in children (n=562,
age 0–17 years) of published data on fluconazole safety showed that at doses of 1–12 mg/kg/
day, 11% of children experienced side effects and 3% discontinued fluconazole therapy due
to side effects. The most commonly reported effects were gastrointestinal (7.7%), and rash
(1.2%). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline
phosphatase elevations were reported in 4.9%, 2.7%, and 2.3% of patients, respectively.23
Fluconazole PK in premature infants
We performed a literature review of the PK of fluconazole in premature infants. We
searched Medline, with the following search terms: fluconazole AND (pharmacokinetics OR
pharmacodynamics) AND (preterm OR premature OR ELBW (extremely low birth weight)
OR VLBW (very low birth weight) OR lbw (low birth weight)) AND limits (newborn – 1
month). This returned 68 abstracts, and 2 authors (KT and ML) determined which were most
appropriate. Five manuscripts were reviewed.16–20
Saxen et al. first described the PK of fluconazole in 12 premature infants receiving
fluconazole prophylaxis.24 The study enrolled infants on postnatal day 1, median gestational
age (GA) of 27.4 weeks (25.9 – 29.4 weeks) and median weight 912 g (750g – 1100g), and
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administered an intravenous dose of 6 mg/kg every 72 hours for 2 weeks. Fluconazole PK
parameters changed rapidly during the first 2 weeks of life. The V increased from 1.18 to
2.25 L/kg, the CL increased from 0.011 L/kg/h to 0.031 L/kg/h, and the t½ decreased from
88.6 to 55.2 hours (Table 1).24, 25
Nahata et al26 examined fluconazole PK in 6 premature infants, median GA of 30 weeks (26
– 40 weeks) and median postnatal age of 51 days (23 – 81 days). All 6 infants received 6
mg/kg of enteral fluconazole, and 2 later received 6 mg/kg of intravenous fluconazole. The
clearance per percent bioavailability (CL/F) ranged from 0.16 to 0.29 ml/min/kg. The peak
serum concentration (Cmax) ranged from 6 to 13.5 µg/mL; and the AUC (0–∞) ranged from
340 to 636 µg*h/mL; and were comparable to IV fluconazole (Table 1). This study provided
preliminary evidence that enteral and IV fluconazole may achieve comparable serum
concentrations in premature infants.
Wenzl et al.27 determined the PK of enteral fluconazole in 3 premature infants, mean GA of
27 weeks (24 – 29 weeks), with Candida sepsis. The infants were given enteral fluconazole
(4.5 – 6 mg/kg/day) and PK samples were obtained on the 20th day of treatment. The V
ranged from 1.21 to 1.88 L/kg, the t½ ranged between 27 to 45 hours, and the AUC ranged
from 131 to 233 µg*h/mL) (Table 1).27 This provided evidence that the dosing was too low
in this population.
Recognizing the need for PK studies in premature infants, investigators in the Pediatric
Pharmacology Research Unit (PPRU) designed and implemented a population PK study.
Fifty-five premature infants were enrolled in a multicenter fluconazole PK study.24 In the
resulting population PK model, investigators found that CL is directly related to GA and
serum creatinine, and doubles during the first month of life (Table 1). Infants with a serum
creatinine >1.3 mg/dL had > 70% reduction in CL. The population PK model was then
externally validated with previously published PK data.24 The authors used Monte Carlo
simulations to calculate target exposures for different prophylaxis and therapeutic dosing
based on gestational age. They demonstrated that, during the first 90 days of life, in an infant
< 30-weeks GA, a fluconazole dose of 12 mg/kg/d would result in an efficacious exposure
(AUC of >400 µg*h/L and an AUC/MIC >50 for Candida strains with an MIC <8 µg/mL) in
>90% of the patients.28 In addition, given the prolonged t½ (30 – 50 hours) in this
population, steady state was not reached until after day 5 of treatment. Therefore, a loading
dose (25 mg/kg) was recommended to achieve the target AUC day 2 of therapy.
Fluconazole loading dose may be needed for premature infants
A fluconazole loading dose approach is commonly used among critically ill adults to reach
fluconazole steady state concentrations early in the treatment course.29–31 A recent study
evaluated the PK of a 25 mg/kg fluconazole loading dose in critically ill infants, median age
of 16 days (interquartile rage [IQR], 13 – 27), GA of 37 weeks (IQR 25 – 38 weeks) and
2.8kg (IQR 2.0 – 3.1kg). Over 60% (5/8 infants) reached the desired therapeutic target
(AUC >400 mg*h/L). Of the 3 failures, 2 had severe anasarca, and the third subject was
supported on an extracorporeal membrane oxygenation (ECMO) circuit.32 These factors
likely influenced their lower AUC observed. It is likely that premature infants need a
loading dose as well, and further investigation is warranted.
Safety in Premature Infants
Relatively few studies have examined the safety of fluconazole in the premature infant.
Most collected data are derived from studies assessing the role of fluconazole as prophylaxis
for IC. Five randomized control trials, consisting of 726 premature infants, evaluated
fluconazole’s effect on hepatotoxicity.33–37 Of these trials, only two studies demonstrated
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stastistically significant increases in AST and ALT, though none of these were considered to
be clinically significant. These values normalized after discontinuation of fluconazole.
Another study evaluated fluconazole hepatotoxicity when being used as prophylaxis in
ELBW infants, and compared liver function tests to historical controls. They found an
increased risk of conjugated hyperbilirubinemia (43% compared to 9%, P<0.001), while on
therapy.38 These values also normalized after discontinuation of fluconazole.
Neurodevelopmental impairment (NDI) is an important long-term outcome for many
premature infants, and it is important to determine if therapeutics have an adverse effect on
NDI. Eighty-six ELBW premature infants were treated with placebo or fluconazole of 3 mg/
kg with increasing dosing frequency (initially dosed every 72h, then progressing to daily
dosing) for 6 weeks. The subjects receiving fluconazole were compared to those receiving
placebo at 8 to 10 years for differences in neurodevelopmental adaptive abilities, behavior,
and quality of life; and the two groups were found to be equivalent.39, 40
In the five phase I studies examining PK of fluconazole in the premature infant, there were
no adverse drug reactions reported. Adverse events of fluconazole in premature infants are
mild and self-limiting, similar to those children and adults. Fluconazole appears to be safe to
use in the premature infant population.
Fluconazole prophylaxis
In premature infants, Candida species progress from colonization to invasive disease. In the
neonatal intensive care unit (NICU), up to 60% of very low birth weight (VLBW) infants
are colonized with Candida in the first month of life.36 Prophylaxis of high-risk patients to
prevent a systemic fungal infection has been investigated with fluconazole, in four
randomized controlled trials.33, 34, 36, 37 A meta-analysis of this data demonstrates
fluconazole to be safe and effective at preventing both colonization and infection with
Candida [relative risk 0.48 (95% CI 0.31, 0.73); number needed to treat (NNT): 11 (95% CI
7, 33)].41 These studies were conducted in centers with a high incidence of Candida, and it
is uncertain if these results would be replicated in low or moderate incidence sites. A
randomized, controlled trial of fluconazole prophylaxis in infants <750 g birth weight has
recently been completed (NCT# 00734539); results are forthcoming.
Summary
IC is common in extremely premature infants and accounts for substantial morbidity and
mortality. Collectively, the PK data reported in this unique, critically ill population
demonstrates that in order to achieve therapeutic concentrations, fluconazole dosing in
premature infants should be 12 mg/kg/day. Moreover, a loading dose (25 mg/kg) may be
required to rapidly achieve appropriate steady state concentrations. These findings differ
substantially from observations in older children and adults and reinforce the need for the
study of the dosing and safety of drugs used in this vulnerable patient population.
Fluconazole appears to be safe to use in this population, with only minimal hepatobiliary
effects that reverse upon discontinuation of therapy. Fluconazole may also have a role in
prophylaxis of IC, especially in centers with high incidence of IC. PK profiles of
therapeutics used in infants must be described using phase I trials, as the PK cannot be
extrapolated from adult data.
Abbreviations
ELBW Extremely low birth weight
VLBW Very low birth weight
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V Volume of distribution
t½ Terminal half life of elimination
Cmax Maximum serum concentration
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